The drug company Lykos Therapeutics had spent much of this year expecting to vault to meteoric heights.
It had sent an application to the Food and Drug Administration seeking approval to use MDMA to treat post-traumatic stress disorder.
It was the capstone to months of increasingly loud concerns being voiced over the quality of Lykos’s clinical trials.
Lykos has spent years conducting clinical trials testing whether MDMA-assisted psychotherapy could alleviate the symptoms of PTSD.
Its most recent drug trial showed that more than 86 percent of people treated had a measurable reduction in symptom severity.
Persons:
”, Lykos
Organizations:
Lykos Therapeutics, Food and Drug Administration, Lykos, Merck